Crossmark

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

Crossref DOI link: https://doi.org/10.1186/s12885-017-3143-6

Published Online: 2017-03-06

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

LoRusso, Patricia M.

Infante, Jeffrey R.

Kim, Kevin B.

Burris, Howard A. III

Curt, Gregory

Emeribe, Ugochi

Clemett, Delyth

Tomkinson, Helen K.

Cohen, Roger B.
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2017-03-06
More Information

Article History

Received: 19 August 2016

Accepted: 15 February 2017

First Online: 6 March 2017